Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. Allos is currently focused on the development and commercialization of FOLOTYN™ (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Allos is also developing FOLOTYN in other potential indications. Allos retains exclusive worldwide rights to FOLOTYN for all indications. Allos is headquartered in Westminster, Colo.| There are currently no events scheduled. |
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|  |  | Webcast
Allos Therapeutics, Inc. at RBC Capital Markets Healthcare Conference (Replay)
03/03/10 at 9:00 a.m. ET |
| Receive E-mail Alerts | | Sign up to receive e-mail alerts whenever Allos Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit. |
| For investor or media-related inquiries, please contact: |
|
